FML by AbbVie is clinical pharmacology corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. Approved for corticosteroid-responsive inflammation of the palpebral, bulbar conjunctiva, cornea and 1 more indications. First approved in 1985.
Drug data last refreshed 26m ago · AI intelligence enriched 1w ago
FML is a topical ophthalmic ointment containing fluorometholone, a corticosteroid approved in 1985 for treating corticosteroid-responsive inflammation of the eye's anterior segment. It works by inhibiting phospholipase A2, thereby suppressing prostaglandin and leukotriene production and reducing inflammatory edema, capillary dilation, and leukocyte migration. The drug is indicated for palpebral and bulbar conjunctivitis, corneal inflammation, and anterior segment uveitis.
Declining market presence with minimal commercial activity signals potential team restructuring and reduced headcount in commercial roles.
CLINICAL PHARMACOLOGY Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen,…
Worked on FML at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on FML represents a sunset assignment in a mature, declining ophthalmic franchise with minimal growth prospects and shrinking commercial support. Career advancement is limited; roles are primarily focused on defensive revenue protection rather than strategic innovation or market expansion.